The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer
Official Title: A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Study ID: NCT02369874
Brief Summary: This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus SoC therapy in the target patient population.
Detailed Description: This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus SoC therapy in the target patient population. The main objectives of the study are to: * assess the efficacy of MEDI4736 + tremelimumab combination therapy versus SoC in patients with squamous cell carcinoma of the head and neck (SCCHN), in terms of overall survival (OS), regardless of PDL-1 status * assess the efficacy of MEDI4736 monotherapy versus SOC in patients with SCCHN, in terms of OS, regardless of PDL-1 status Patients will undergo a screening assessment on their tumor tissue sample to determine PD-L1 expression per a pre-specified cut-off level. Patients with ≥25% of tumor cells with membrane staining will be considered PD-L1 positive while those with 0% to 24% of tumor cells with membrane staining will be considered PD-L1 negative. Based on the underlying PD-L1 status, patients will be randomized in a 1:1:1 ratio to receive treatment with MEDI4736 monotherapy, MEDI4736 + tremelimumab combination therapy, or SoC therapy. Patients who discontinue treatment in 1 treatment group may not switch to treatment in a different group. Stratification factors include PD-L1 status, human papillomavirus status, (in patients with oropharyngeal cancer only), and smoking status. Tumor assessments will be performed every 8 weeks until objective tumor response by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Research Site, Tucson, Arizona, United States
Research Site, Fullerton, California, United States
Research Site, Los Angeles, California, United States
Research Site, Redondo Beach, California, United States
Research Site, Stanford, California, United States
Research Site, Denver, Colorado, United States
Research Site, Newark, Delaware, United States
Research Site, Miami Beach, Florida, United States
Research Site, Orlando, Florida, United States
Research Site, Atlanta, Georgia, United States
Research Site, Evanston, Illinois, United States
Research Site, Lexington, Kentucky, United States
Research Site, Boston, Massachusetts, United States
Research Site, Rochester, New York, United States
Research Site, Rochester, New York, United States
Research Site, Winston-Salem, North Carolina, United States
Research Site, Pittsburgh, Pennsylvania, United States
Research Site, Germantown, Tennessee, United States
Research Site, Nashville, Tennessee, United States
Research Site, Dallas, Texas, United States
Research Site, Dallas, Texas, United States
Research Site, McAllen, Texas, United States
Research Site, Norfolk, Virginia, United States
Research Site, Caba, , Argentina
Research Site, San Miguel de Tucuman, , Argentina
Research Site, Adelaide, , Australia
Research Site, Heidelberg, , Australia
Research Site, Melbourne, , Australia
Research Site, St Leonards, , Australia
Research Site, Woolloongabba, , Australia
Research Site, Brussels, , Belgium
Research Site, Bruxelles, , Belgium
Research Site, Charleroi, , Belgium
Research Site, Kortrijk, , Belgium
Research Site, Leuven, , Belgium
Research Site, Namur, , Belgium
Research Site, Barretos, , Brazil
Research Site, Curitiba, , Brazil
Research Site, Porto Alegre, , Brazil
Research Site, Porto Alegre, , Brazil
Research Site, Rio de Janeiro, , Brazil
Research Site, Santo Andre, , Brazil
Research Site, São José do Rio Preto, , Brazil
Research Site, São Paulo, , Brazil
Research Site, Shumen, , Bulgaria
Research Site, Sofia, , Bulgaria
Research Site, Varna, , Bulgaria
Research Site, Temuco, , Chile
Research Site, Osijek, , Croatia
Research Site, Zagreb, , Croatia
Research Site, Olomouc, , Czechia
Research Site, Zlin, , Czechia
Research Site, Angers, , France
Research Site, Bordeaux, , France
Research Site, Dijon, , France
Research Site, Le Mans, , France
Research Site, Lyon Cedex 08, , France
Research Site, Montpellier Cedex 5, , France
Research Site, Paris Cedex 5, , France
Research Site, Plerin SUR MER, , France
Research Site, Rouen, , France
Research Site, St Grégoire, , France
Research Site, Strasbourg Cedex, , France
Research Site, Villejuif Cedex, , France
Research Site, Lorient Cedex, , Georgia
Research Site, Berlin, , Germany
Research Site, Essen, , Germany
Research Site, Halle, , Germany
Research Site, Hannover, , Germany
Research Site, Heidelberg, , Germany
Research Site, Leipzig, , Germany
Research Site, München, , Germany
Research Site, Potsdam, , Germany
Research Site, Budapest, , Hungary
Research Site, Budapest, , Hungary
Research Site, Budapest, , Hungary
Research Site, Gyor, , Hungary
Research Site, Kecskemét, , Hungary
Research Site, Haifa, , Israel
Research Site, Jerusalem, , Israel
Research Site, Petach-Tikva, , Israel
Research Site, Tel Aviv, , Israel
Research Site, Tel Hashomer, , Israel
Research Site, Aosta, , Italy
Research Site, Bologna, , Italy
Research Site, Gallarate, , Italy
Research Site, Legnago, , Italy
Research Site, Milano, , Italy
Research Site, Napoli, , Italy
Research Site, Pavia, , Italy
Research Site, Roma, , Italy
Research Site, Siena, , Italy
Research Site, Chuo-ku, , Japan
Research Site, Fukuoka-shi, , Japan
Research Site, Hirakata-shi, , Japan
Research Site, Isehara-shi, , Japan
Research Site, Kashiwa, , Japan
Research Site, Kitaadachi-gun, , Japan
Research Site, Kobe-shi, , Japan
Research Site, Koto-ku, , Japan
Research Site, Matsuyama-shi, , Japan
Research Site, Nagoya, , Japan
Research Site, Natori-shi, , Japan
Research Site, Okayama, , Japan
Research Site, Osakasayama, , Japan
Research Site, Osaka, , Japan
Research Site, Sapporo, , Japan
Research Site, Sapporo, , Japan
Research Site, Shimotsuke-shi, , Japan
Research Site, Sunto-gun, , Japan
Research Site, Takatsuki-shi, , Japan
Research Site, Yokohama-shi, , Japan
Research Site, Yokohama, , Japan
Research Site, Daegu, , Korea, Republic of
Research Site, Goyang-si, , Korea, Republic of
Research Site, Seoul, , Korea, Republic of
Research Site, Seoul, , Korea, Republic of
Research Site, Suwon, , Korea, Republic of
Research Site, Kraków, , Poland
Research Site, Poznań, , Poland
Research Site, Łódź, , Poland
Research Site, Baia Mare, , Romania
Research Site, Brasov, , Romania
Research Site, Cluj-Napoca, , Romania
Research Site, Cluj, , Romania
Research Site, Craiova, , Romania
Research Site, Arkhangelsk, , Russian Federation
Research Site, Chelyabinsk, , Russian Federation
Research Site, Kursk, , Russian Federation
Research Site, Moscow, , Russian Federation
Research Site, Moscow, , Russian Federation
Research Site, Moscow, , Russian Federation
Research Site, Moscow, , Russian Federation
Research Site, Moscow, , Russian Federation
Research Site, Nizhniy Novgorod, , Russian Federation
Research Site, Omsk, , Russian Federation
Research Site, Pyatigorsk, , Russian Federation
Research Site, Saint Petersburg, , Russian Federation
Research Site, Saint-Petersburg, , Russian Federation
Research Site, Sankt-Peterburg, , Russian Federation
Research Site, Sochi, , Russian Federation
Research Site, Ufa, , Russian Federation
Research Site, Vladimir, , Russian Federation
Research Site, Belgrade, , Serbia
Research Site, Belgrad, , Serbia
Research Site, Kragujevac, , Serbia
Research Site, Nis, , Serbia
Research Site, Sremska Kamenica, , Serbia
Research Site, Barcelona, , Spain
Research Site, Barcelona, , Spain
Research Site, L'Hospitalet de Llobregat, , Spain
Research Site, Madrid, , Spain
Research Site, Madrid, , Spain
Research Site, Madrid, , Spain
Research Site, Malaga, , Spain
Research Site, Marbella, , Spain
Research Site, Pamplona, , Spain
Research Site, Valencia, , Spain
Research Site, Valencia, , Spain
Research Site, Zaragoza, , Spain
Research Site, Kaohsiung, , Taiwan
Research Site, Taipei, , Taiwan
Research Site, Taipei, , Taiwan
Research Site, Taoynan, , Taiwan
Research Site, Dnipro, , Ukraine
Research Site, Kyiv, , Ukraine
Research Site, Sumy, , Ukraine
Research Site, Uzhhorod, , Ukraine
Research Site, Zaporizhzhia, , Ukraine
Name: Nassim Morsli, MD
Affiliation: Medical Director AstraZeneca
Role: STUDY_DIRECTOR